Neovasc Inc. Current Part of Debt

Current Part of Debt of NVCN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Part of Debt growth rates and interactive chart. Current debt or short-term debt are a firm's financial obligations that are expected to be paid off within a year. It also includes the portion of long-term debt that is due within a year. It is a part of the overall indebtedness of a company, and is included in Debt/Equity and Debt/Assets ratios.


Highlights and Quick Summary

  • Current Part of Debt for the quarter ending December 31, 2021 was $350 Thousand (a -39.66% decrease compared to previous quarter)
  • Year-over-year quarterly Current Part of Debt decreased by -40.75%
  • Annual Current Part of Debt for 2021 was $350 Thousand (a -16.63% decrease from previous year)
  • Annual Current Part of Debt for 2020 was $420 Thousand (a -93.92% decrease from previous year)
  • Annual Current Part of Debt for 2019 was $6.91 Million (a 383.45% increase from previous year)
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Part of Debt of Neovasc Inc.

Most recent Current Part of Debtof NVCN including historical data for past 10 years.

Interactive Chart of Current Part of Debt of Neovasc Inc.

Neovasc Inc. Current Part of Debt for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.35 $0.58 $0.37 $0.59 $0.35
2020 $0.42 $0.3 $0.96 $5.09 $0.42
2019 $6.49 $8.95 $9.63 $0.73 $6.91
2018 $1.42 $0.65 $3.58 $4.26 $1.43
2017 $4.26 $4.27
2016 $70.0
2015 $0.03
2014 $0.04 $0.04 $0.03 $0.04
2013 $0.04 $0.04 $0.04 $0.04 $0.04
2012 $0.04 $0.04 $0.04 $0.04 $0.04
2011 $0.04 $0.04

Business Profile of Neovasc Inc.

Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.